RNA (Atrium Therapeutics) Research & Development: $35.15 Mil (TTM As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $12.80
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Research & Development?

Atrium Therapeutics RNA +0.16% 12 Research & Development is $35.15 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Atrium Therapeutics's Research & Development for the three months ended in Mar. 2026 was $16.66 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $35.15 Mil.

Atrium Therapeutics  (NAS:RNA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Atrium Therapeutics Research & Development Related Terms

Atrium Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Research & Development Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
12.65 19.20 53.76

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial 7.52 6.94 0.00 18.50 16.66
RNA
12GF Score
Atrium Therapeutics Inc RNA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $35.15 Mil mean?
Atrium Therapeutics (RNA) has a Research & Development of $35.15 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Research & Development too high?
Atrium Therapeutics' current Research & Development is $35.15 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Research & Development compare to RNAC and KROS?
Atrium Therapeutics' Research & Development of $35.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Research & Development is $35.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Research & Development of $35.15 Mil. The current Research & Development is $35.15 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Research & Development is $35.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.80
Price